Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is trading higher on being issued another utility patent for its novel DurAVR™ transcatheter heart valve (THV).
The US Patent and Trademark Office continues to recognise DurAVR™ THV as a first-in-class biomimetic valve uniquely designed to mimic the performance of a healthy human heart valve.
The patent number 11,648,107 expires on September 12, 2038. It provides additional Intellectual Property (IP) protection for the differentiated heart valve technology and covers new claims that are additive to the existing IP coverage for DurAVR™ THV.
It also protects the innovative single-piece tissue design with molded leaflets and commissures attached to a frame.
This new patent confirms AVR’s ability to build a broad IP portfolio around DurAVR™ THV.
Excellent clinical results
Anteris believes its excellent clinical results to date are down to the unique aspects of the DurAVR™ design, including the single-piece valve construction and leaflet design.
“The awarding of this patent continues to highlight our culture of innovation and the extraordinary work by our team of engineers around the world responsible for the design of DurAVR™ THV,” Anteris CEO Wayne Paterson said.
“This new patent further enhances our broad IP protection for DurAVR™ THV and strengthens our competitive position in the TAVR field.”
Investors have welcomed the development with AVR shares as much as 4.33% higher in the first half hour of ASX trading to $A22.44.